Seagen(US:SGEN)2025-04-28 13:16Business Overview and Growth Strategy - Seagen is focused on maximizing the global potential of its three approved products through clinical development and commercial execution[6, 8] - The company aims to advance late-stage programs towards securing approvals for new products[6, 37] - Seagen intends to expand its early-stage pipeline through internal R&D, ADC leadership, and strategic corporate development[6, 44] Product Performance and Sales - Net product sales increased 60% in 3Q20 compared to 3Q19, driven by the addition of PADCEV and TUKYSA to the commercial portfolio[12] - Total revenues for the three months ended September 30, 2020, were $1.1 billion[48] - Total revenues for the nine months ended September 30, 2020, were $1.6 billion[48] - ADCETRIS U S /Canada net sales were $163.3 million for the three months ended September 30, 2020[48] - PADCEV U S net sales were $61.8 million for the three months ended September 30, 2020[48] - TUKYSA U S net sales were $42.4 million for the three months ended September 30, 2020[48] Clinical Development and Regulatory Milestones - A BLA submission for tisotumab vedotin (TV) is planned for 1Q21[38] - PADCEV's EV-201 cohort 2 and EV-301 supplemental BLA is planned in 1Q21[22] - The company is advancing 10 registrational trials across ADCETRIS, PADCEV, and TUKYSA[53] - Ladiratuzumab vedotin (LV) global collaboration with Merck for development and commercialization[5, 43]